Wize Pharma

Wize Pharma is a dynamic clinical-stage biopharmaceutical company dedicated to advancing the treatment of ophthalmic disorders. Focused on innovative solutions, Wize Pharma is committed to improving patient outcomes and quality of life through the development and commercialization of cutting-edge therapies.

Located in Hod Hasharon, Israel 4527713, IL, Wize Pharma has in-licensed rights to LO2A, a drug formulated for the treatment of Dry Eye Syndrome (DES) and other ophthalmological conditions, including Conjunctivochalasis (CCh) and Sjögren's syndrome. LO2A is already registered and marketed in several European countries, and Wize Pharma is strategically engaging distributors to expand its reach.

Wize Pharma is dedicated to conducting rigorous clinical trials and studies to ensure the efficacy and safety of its products. With a focus on innovation and patient-centric care, Wize Pharma continues to make significant strides in the field of ophthalmology. We invite the management team at Wize Pharma to enhance your company's visibility by creating a customized and exclusive company showcase and product listing on our platform.